Get the Stockscreener App
2.025
6.48%
-0.135
Inmune Bio Inc stock is traded at $2.025, with a volume of 423.19K.
It is down -6.48% in the last 24 hours and down -12.93% over the past month.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
See More
Previous Close:
$2.16
Open:
$2.15
24h Volume:
423.19K
Relative Volume:
0.59
Market Cap:
$56.14M
Revenue:
$50,000
Net Income/Loss:
$-41.60M
P/E Ratio:
-1.195
EPS:
-1.6946
Net Cash Flow:
$-20.20M
1W Performance:
-1.46%
1M Performance:
-12.93%
6M Performance:
+62.90%
1Y Performance:
+1.51%
1-Day Range:
$1.99
$2.175
1-Week Range:
$1.99
$2.4199
52-Week Range:
$1.09
$2.60
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
2.0229 | 59.95M | 50,000 | -41.60M | -20.20M | -1.6946 |
VRTX
Vertex Pharmaceuticals Inc
|
514.51 | 130.53B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
802.04 | 82.77B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
183.27 | 72.88B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
945.16 | 60.30B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
364.63 | 41.64B | 5.76B | 514.49M | 1.10B | 4.4813 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
Form 4 INmune Bio Inc For: 23 September - Investing.com India
Inmune Bio (INMB) gives director 3-year option grant - Stock Titan
[Form 3] Inmune Bio, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Inmune Stock Price Forecast. Should You Buy INMB? - StockInvest.us
Inmune Bio (NASDAQ: INMB) grants 100,000 stock options to new director - Stock Titan
New Inmune Bio (INMB) director reports no shares - Stock Titan
Inmune Bio Adds Strategic Directors to Support Commercialization - TipRanks
INmune Bio, Inc. Announces Board Appointments - marketscreener.com
INmune Bio at H.C. Wainwright conference: rdeB drug nears filings By Investing.com - Investing.com Canada
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board - Yahoo Finance
A Sanofi rare-disease leader joins INmune Bio's board for a possible treatment launch. - Stock Titan
INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial? - Stocktwits
INmune Bio to Present at the H.C. Wainwright Global Investment Conference - Yahoo Finance
INmune Bio Inc (INMB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Inmune Bio stock steadies as investors await next data catalyst - ad-hoc-news.de
INmune Bio undervalued as Ebstrocel for RDEB ne... - Pluang
INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment (NASDAQ:INMB) - Seeking Alpha
aTyr Pharma And 2 Other Penny Stocks With Promising Potential - Sahm
INmune Bio submits EU regulatory filings for Ebstrocel in RDEB By Investing.com - Investing.com Canada
INmune Bio (INMB) Climbs 4.33% to $2.17 as Traders Test Key Resistance at $2.28Put Spread Alert - dars.gov.et
INmune Bio Inc (INMB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
INmune Bio (INMB) Q2 2026 Earnings Call Transcript - AOL.com
INmune Bio Advances Ebstrocel Regulatory Filings and Clinical Plans - sekbernews.id
INmune Bio (NASDAQ:INMB) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Q2 2026 INmune Bio Inc Earnings Call Transcript - GuruFocus
Earnings call transcript: INmune Bio posts narrower Q2 2026 loss, eyes filings - Investing.com South Africa
INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress - The Manila Times
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regula - GuruFocus
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regulatory Wins and Strategic Focus ... - Yahoo Finance
INmune Bio, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
INmune Bio Q2 Earnings Call Highlights - MarketBeat
INmune Bio Q2 2026 Earnings: Tax-Credit Benefit Narrows Net Loss - TradingKey
INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Beats Expectations By $0.16 EPS - MarketBeat
INMB: Ebstrocel nears global filings as financials strengthen and XPro advances in Alzheimer's - TradingView
INmune Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Inmune Bio, Inc. Q2 2026: Revenue $0 Net loss $(1.27)M, EPS $(0.05) — 10-Q Summary - TradingView
INmune Bio Q2 net loss narrows on lower impairment charges - TradingView
INmune Bio (NASDAQ: INMB) posts $6.7M loss and warns on cash runway - Stock Titan
10-Q: INmune Bio | 10-Q: Q2 2026 Earnings Report - Moomoo
INmune Bio Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
INmune Bio receives $4.6M in R&D rebates from Australia, UK - Investing.com UK
INmune Bio Strengthens Cash Runway With R&D Rebates - TipRanks
INmune Bio receives ~$4.6M in R&D rebates, cash proceeds exceed Q2 operating cash use - TradingView
INmune Bio (INMB.US) will release its earnings report after market close on August 6. - moomoo.com
INmune Bio Inc.Common stock (INMB) Stock Price, News, Quote & History - FinancialContent
INmune Bio Receives $4.2 Million Australia R&D Rebate, Extending Cash Runway for CORDStrom Development - Quiver Quantitative
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on ... - Caledonian Record
INmune Bio schedules Aug. 6 webcast on second-quarter results - Stock Titan
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th - Yahoo Finance
INmune Bio forms scientific advisory board for cell therapy By Investing.com - Investing.com Nigeria
INMB Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inmune Bio Inc Stock (INMB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lowdell Mark William | Chief Scientific Officer |
Jul 02 '26 |
Option Exercise |
1.40 |
7,211 |
10,095 |
1,518,017 |
| Moss David J | Chief Executive Officer |
Jul 02 '26 |
Option Exercise |
1.40 |
9,014 |
12,620 |
1,294,883 |
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):